• Corpus ID: 33852376

Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes.

@article{Otton1988UseOQ,
  title={Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes.},
  author={S. Victoria Otton and H. Kim Crewe and Martin S. Lennard and Geoffrey T Tucker and H. F. Woods},
  journal={The Journal of pharmacology and experimental therapeutics},
  year={1988},
  volume={247 1},
  pages={
          242-7
        }
}
  • S. OttonH. Crewe H. Woods
  • Published 1 October 1988
  • Biology, Chemistry
  • The Journal of pharmacology and experimental therapeutics
The oxidation of the beta adrenoceptor antagonist metoprolol exhibits genetic polymorphism of the sparteine/debrisoquine (SP/DB) type. The alpha-hydroxylation of metoprolol is absent in poor metabolizers, whereas metoprolol O-demethylation is only partially impaired, suggesting that an enzyme or enzymes other than cytochrome P450-SP/DB contribute to the latter reaction. Using inhibition by the quinidine/quinine isomer pair as a marker for the activity of cytochrome P450-SP/DB, the role of this… 

The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes.

It is concluded that, in man, the initial step of paroxetine metabolism is performed by at least two enzymes, one of which is cytochrome P4502D6.

Identification of cytochrome P450 enzymes involved in the metabolism of zotepine, an antipsychotic drug, in human liver microsomes.

The results suggest that both the N-demethylation and S-oxidation of zotepine are mediated mainly by CYP3A4, and that CYP1A2 and 2D6 play an important role in the 2- and 3-hydroxylation of zOTepine, respectively.

Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo.

The in vitro model correctly identifies ritonavir as a potent and clinically important inhibitor of human P450-2D6, and other protease inhibitors may also inhibit 2D6 activity in humans, but with lower potency than ritonvir.

Identification of cytochrome P450 isozymes involved in metabolism of the alpha1-adrenoceptor blocker tamsulosin in human liver microsomes.

It is concluded that formation of tamsulosin metabolites, AM-1 and M-1, is catalysed by CYP3A4 whereas that of M-3 andM-4 isCatalysed by CyP2D6, however, minor contributions from other CYPs cannot be excluded.

Inhibition of CYP2D6 activity by treatment with propranolol and the role of 4-hydroxy propranolol.

Although treatment with propranolol 80 mg twice daily significantly decreases the catalytic function of CYP2D6, the inhibition is insufficient to result in phenocopying, and the reactive intermediate produced by further metabolism of 4OHP is probably scavenged effectively in vivo by glutathione and other nucleophiles.

Propranolol oxidation by human liver microsomes--the use of cumene hydroperoxide to probe isoenzyme specificity and regio- and stereoselectivity.

The findings suggest that P450IID6 is involved in both the 4- and 5-hydroxylations of propranolol, but that these metabolites can also be formed by other P450 isoenzymes.

Regio- and Stereo-Selective Oxidation of a Cardiovascular Drug, Metoprolol, Mediated by Cytochrome P450 2D and 3A Enzymes in Marmoset Livers

The results indicated that the major roles of P450 2D enzymes for the regio- and stereo-selectivity of metoprolol oxidation were similar between human and marmoset livers, but the minor roles ofP450 3A enzymes were unique to marmosets.

Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone.

CYP2C8 is primarily responsible for the hydroxylation and N-demethylation of rosiglitazone in human liver; with minor contributions from CYP2C9.

Sparteine metabolism capacity in human liver: structural variants of human P450IID6 as assessed by immunochemistry.

An antibody raised against rat P450dbl was used to examine the heterogeneity of the human enzyme involved in the sparteine/debrisoquine polymorphism and variation in inhibition by this antibody reflected the amount of P450IID6 protein.

4-Hydroxylation of debrisoquine by human CYP1A1 and its inhibition by quinidine and quinine.

Findings have significant implications for the conduct of in vitro drug metabolism inhibition studies and underscore the fallacy of "specific chemical inhibitors" of a supergene family of enzymes that have overlapping substrate specificities.
...